146 related articles for article (PubMed ID: 9039130)
1. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense.
Phillips MI; Mohuczy-Dominiak D; Coffey M; Galli SM; Kimura B; Wu P; Zelles T
Hypertension; 1997 Jan; 29(1 Pt 2):374-80. PubMed ID: 9039130
[TBL] [Abstract][Full Text] [Related]
2. Antisense inhibition of AT1 receptor in vascular smooth muscle cells using adeno-associated virus-based vector.
Mohuczy D; Gelband CH; Phillips MI
Hypertension; 1999 Jan; 33(1 Pt 2):354-9. PubMed ID: 9931129
[TBL] [Abstract][Full Text] [Related]
3. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
Phillips MI
Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
[TBL] [Abstract][Full Text] [Related]
4. Recombinant adeno-associated virus-mediated delivery of antisense angiotensin II receptor 1 gene attenuates hypertension development.
Li XG; Yan JT; Xu XZ; Wang JN; Cheng LM; Wang T; Zuo P; Wang DW
Acta Pharmacol Sin; 2007 Nov; 28(11):1737-45. PubMed ID: 17959024
[TBL] [Abstract][Full Text] [Related]
5. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension.
Tang X; Mohuczy D; Zhang YC; Kimura B; Galli SM; Phillips MI
Am J Physiol; 1999 Dec; 277(6):H2392-9. PubMed ID: 10600860
[TBL] [Abstract][Full Text] [Related]
6. Somatic gene therapy for hypertension.
Phillips MI
Braz J Med Biol Res; 2000 Jun; 33(6):715-21. PubMed ID: 10829100
[TBL] [Abstract][Full Text] [Related]
7. Long-term inhibition of the central alpha(2B)-adrenergic receptor gene via recombinant AAV-delivered antisense in hypertensive rats.
Shenouda SM; Johns C; Kintsurashvili E; Gavras I; Gavras H
Am J Hypertens; 2006 Nov; 19(11):1135-43. PubMed ID: 17070424
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for hypertension: sense and antisense strategies.
Phillips MI
Expert Opin Biol Ther; 2001 Jul; 1(4):655-62. PubMed ID: 11727501
[TBL] [Abstract][Full Text] [Related]
9. Long-term modifications of blood pressure in normotensive and spontaneously hypertensive rats by gene delivery of rAAV-mediated cytochrome P450 arachidonic acid hydroxylase.
Zhang F; Chen CL; Qian JQ; Yan JT; Cianflone K; Xiao X; Wang DW
Cell Res; 2005 Sep; 15(9):717-24. PubMed ID: 16212878
[TBL] [Abstract][Full Text] [Related]
10. Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats.
Gyurko R; Tran D; Phillips MI
Am J Hypertens; 1997 May; 10(5 Pt 2):56S-62S. PubMed ID: 9160782
[TBL] [Abstract][Full Text] [Related]
11. Delivery of antisense DNA by vectors for prolonged effects in vitro and in vivo.
Mohuczy D; Tang X; Phillips MI
Methods Enzymol; 2000; 314():32-51. PubMed ID: 10565003
[No Abstract] [Full Text] [Related]
12. Attenuation of hypertension by systemic delivery of retroviral vector containing type I angiotensin II receptor antisense cDNA.
Reaves PY; Wang HW; Katovich MJ; Gelband CH; Raizada MK
Methods; 2000 Nov; 22(3):211-8. PubMed ID: 11071816
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy.
Pachori AS; Numan MT; Ferrario CM; Diz DM; Raizada MK; Katovich MJ
Hypertension; 2002 May; 39(5):969-75. PubMed ID: 12019278
[TBL] [Abstract][Full Text] [Related]
14. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.
Peng JF; Kimura B; Fregly MJ; Phillips MI
Hypertension; 1998 Jun; 31(6):1317-23. PubMed ID: 9622148
[TBL] [Abstract][Full Text] [Related]
15. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element.
Haberman RP; McCown TJ; Samulski RJ
J Virol; 2000 Sep; 74(18):8732-9. PubMed ID: 10954575
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense.
Kimura B; Mohuczy D; Tang X; Phillips MI
Hypertension; 2001 Feb; 37(2 Pt 2):376-80. PubMed ID: 11230303
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries.
Wang T; Li H; Zhao C; Chen C; Li J; Chao J; Chao L; Xiao X; Wang DW
Gene Ther; 2004 Sep; 11(17):1342-50. PubMed ID: 15175642
[TBL] [Abstract][Full Text] [Related]
18. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids.
Booth MJ; Mistry A; Li X; Thrasher A; Coffin RS
Gene Ther; 2004 May; 11(10):829-37. PubMed ID: 14985784
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid.
Phillips MI
Am J Cardiol; 1998 Nov; 82(10A):60S-62S. PubMed ID: 9860363
[No Abstract] [Full Text] [Related]
20. Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene.
Peng L; Sidner RA; Bochan MR; Burton MM; Cooper ST; Jindal RM
J Surg Res; 1997 Apr; 69(1):193-8. PubMed ID: 9202669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
